Американское общество гирудотерапии

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Review published in The Annals of thoracic surgery (2000)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewКлинические исследованияРазработка лекарственных препаратовFrederiksen · The Annals of thoracic surgery, 2000

Abstract

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation. Unfortunately, each alternative currently lacks a standard dosing schedule and a reliable method of monitoring the adequacy of its anticoagulant effect during CPB. Most also lack proven antidotes. Thus, unfractionated heparin remains the anticoagulant of choice for standard CPB.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassDose-Response Relationship, DrugDrug Administration ScheduleHeparinHumansThrombocytopenia

Резюме

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation.

Почему это важно для гирудотерапии

This review discusses seven anticoagulants used as alternatives to unfractionated heparin during human cardiopulmonary bypass, primarily in patients with heparin-induced thrombocytopenia. The authors note that each alternative currently lacks a standard dosing schedule, a reliable monitoring method for anticoagulant adequacy during bypass, and, in most cases, a proven antidote, leaving unfractionated heparin as the anticoagulant of choice for standard cardiopulmonary bypass. The abstract does not mention leeches, hirudin, hirudotherapy, or any leech-derived molecules. The article's connection to the American Society of Hirudotherapy is therefore nonexistent based on the abstract alone, as it focuses entirely on conventional anticoagulant alternatives for surgical bypass.

Цитирование

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Frederiksen · The Annals of thoracic surgery, 2000

Связанный клинический контекст

Добавлено в библиотеку ASH: May 28, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.